Showing 4671-4680 of 5314 results for "".
- Study: Positive Safety and Tolerability Results for Ortho Dermatologics' Altreno for Acnehttps://practicaldermatology.com/news/study-positive-results-for-ortho-dermatologics-altrenos-safety-and-tolerability-for-acne/2457569/Ortho Dermatologics shared results of two identical Phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel group studies examining the efficacy and safety of Altreno (tretinoin) Lotion, 0.05%, the first formulation of tretinoin, a retinoid, in a lotion indicated for the topi
- Dermira's Qbrexa Cloth Now Available for Primary Axillary Hyperhidrosishttps://practicaldermatology.com/news/dermiras-qbrexa-cloth-now-available-for-primary-axillary-hyperhidrosis/2457582/Dermira, Inc.'s Qbrexa (glycopyrronium) cloth is now available for prescribing to treat primary axillary hyperhidrosis. The new therapy is available in retail and community pharmacies nationwide. In June 2018, QBREXZA, a once-daily, prescription anticholinergic, was FDA approved to treat adul
- Is Teen Acne a Sign of Future Financial Success?https://practicaldermatology.com/news/is-teen-acne-a-sign-of-future-financial-success/2457586/The love of books, the need for glasses and high intelligence are traits found among the top earners in many fields across the country, and now, a Ball State University researcher suggests that teen acne may also be on this list. In his study, “
- Bellus Medical Now Part of Crown Laboratorieshttps://practicaldermatology.com/news/bellus-medical-now-part-of-crown-laboratories/2457590/Crown Laboratories, Inc. and Hildred Capital Partners, LLC have acquired Bellus Medical. Bellus’s non-invasive offerings include the SkinPen, a medical grade microneedling device used exclusively by healthcare professionals to improve the appearance of facial acne scars. It is the f
- Nestle to Explore Strategic Options for Skin Health Divisionhttps://practicaldermatology.com/news/nestle-to-explore-strategic-options-for-skin-health-division/2457597/...After further analysis and consideration, the Board has come to the conclusion that the future growth opportunities of Nestlé Skin Health lie increasingly outside the Group’s strategic scope
- Experts Call for Improved Identification of "High Burden" Rosacea Patients in Everyday Practicehttps://practicaldermatology.com/news/experts-call-for-improved-identification-of-high-burden-rosacea-patients-in-everyday-practice/2457605/Additional analysis of a global survey conducted and presented earlier this year, as an expert-authored report called Rosacea: Beyond the visible, assists healthcare professionals in identifying the common char
- Kuleana Debuts Natural, Reef-Safe Sunscreenhttps://practicaldermatology.com/news/kuleana-debuts-natural-reef-safe-sunscreen/2457601/Amid growing concerns that certain sunscreen ingredients are harming coral reefs and marine life, Hawaiian company Kuleana is rolling out a natural sunscreen that is free from oxybenzone and octinoxate – two chemicals known to be toxic to corals and other marine life that were recently bann
- New Study Examines Safety and Efficacy of Higher Dose Botox Cosmetichttps://practicaldermatology.com/news/new-study-examines-safety-and-efficacy-of-higher-dose-botox-cosmetic/2457609/Allergan plc conducted a clinical trial to evaluate the duration of effect and safety of Botox Cosmetic 40, 60, and 80 unit doses versus Botox Cosmetic 20 unit dose in patients with moderate to severe glabellar lines. The primary efficacy endpoint was met and was statistically significant f
- First-Ever Molecular Study Shows African American Skin Reacts Differently to ADhttps://practicaldermatology.com/news/first-ever-molecular-study-shows-african-american-skin-reacts-differently-to-ad/2457612/African Americans are known to have greater treatment challenges with atopic dermatitis than European Americans and require higher doses of some medications to get relief, and now a new study suggests that differences in the molecular profile of their skin may be the reason. About 19 perc
- Breaking Business News: Allergan Acquires Bontihttps://practicaldermatology.com/news/breaking-business-news-allergan-aquires-bonti/2457610/Allergan acquired Bonti, Inc., a privately held clinical-stage biotechnology company focused on the development and commercialization of novel, fast-acting neurotoxin programs for aesthetic and therapeutic applications. Following completion of the acquisition, Allergan will obtain global